Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Bauer

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2013
Pros and cons of new oral anticoagulantsKenneth A Bauer
Hematology. American Society of Hematology. Education Program|December 9, 2023
The dos, don'ts, and nuances of thrombophilia testingThita Chiasakul, Kenneth A Bauer
Annals of Internal Medicine|April 18, 2012
ACP Journal Club. Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patientsDavid Feinbloom, Kenneth A Bauer
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2006
The role of other hemostatic factors in predicting arterial thrombotic eventsDavid Feinbloom, Kenneth A Bauer
Arteriosclerosis, Thrombosis, and Vascular Biology|August 16, 2005
Assessment of hemostatic risk factors in predicting arterial thrombotic eventsDavid Feinbloom, Kenneth A Bauer
Hematology. American Society of Hematology. Education Program|December 4, 2020
Thrombolytic therapy in acute venous thromboembolismThita Chiasakul, Kenneth A Bauer
Blood|January 10, 2020
Managing thromboembolic risk in patients with hereditary and acquired thrombophiliasJason Moran, Kenneth A Bauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosisJeffrey I Zwicker, Kenneth A Bauer
Journal of Thrombosis and Haemostasis : JTH|September 21, 2023
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfaJustine H Ryu, Kenneth A Bauer, Sol Schulman
Allergy and Asthma Proceedings|January 14, 2015
The thrombogenicity of C1 esterase inhibitor (human): review of the evidenceMark Crowther, Kenneth A Bauer, Allen P Kaplan
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Hematology. American Society of Hematology. Education Program|December 10, 2013
Pros and cons of new oral anticoagulantsKenneth A Bauer
Hematology. American Society of Hematology. Education Program|December 9, 2023
The dos, don'ts, and nuances of thrombophilia testingThita Chiasakul, Kenneth A Bauer
Annals of Internal Medicine|April 18, 2012
ACP Journal Club. Enoxaparin thrombophylaxis did not reduce mortality in acutely ill medical patientsDavid Feinbloom, Kenneth A Bauer
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2006
The role of other hemostatic factors in predicting arterial thrombotic eventsDavid Feinbloom, Kenneth A Bauer
Arteriosclerosis, Thrombosis, and Vascular Biology|August 16, 2005
Assessment of hemostatic risk factors in predicting arterial thrombotic eventsDavid Feinbloom, Kenneth A Bauer
Hematology. American Society of Hematology. Education Program|December 4, 2020
Thrombolytic therapy in acute venous thromboembolismThita Chiasakul, Kenneth A Bauer
Blood|January 10, 2020
Managing thromboembolic risk in patients with hereditary and acquired thrombophiliasJason Moran, Kenneth A Bauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosisJeffrey I Zwicker, Kenneth A Bauer
Journal of Thrombosis and Haemostasis : JTH|September 21, 2023
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfaJustine H Ryu, Kenneth A Bauer, Sol Schulman
Allergy and Asthma Proceedings|January 14, 2015
The thrombogenicity of C1 esterase inhibitor (human): review of the evidenceMark Crowther, Kenneth A Bauer, Allen P Kaplan
Pageof 10